Phase I/II – First Administration

443 trials 187 recruiting

Filter these 443 trials by condition, country, sponsor and more.

Open in Search →

A Safety, Tolerability, and Efficacy Study of VX-264 in Subjects With Type 1 Diabetes Ended

2024-515583-32-00 Type 1 Diabetes Mellitus 2023-07-06
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD). Ended

2022-501250-12-01 Inherited retinal dystrophies 2023-03-17
Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Ended

2023-510351-31-00 Duchenne muscular dystrophy 2023-01-06
A trial to determine the safety and tolerability of transplanted stem cellderived dopamine neurons to the brains of individuals with Parkins… Ended

2024-511237-35-00 Parkinson's disease 2022-11-30
A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid Tumors Ended

2024-512120-11-00 Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast 2022-08-31
ATA-100 gene therapy trial in patients with limb-girdle muscular dystrophy Ended

2023-506677-36-00 FKRP-related limb-girdle muscular dystrophy (LGMD R9) 2022-07-18
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias… Ended

2024-513759-34-00 Relapsed or Refractory Acute Leukemias 2022-05-31
A phase 1/1b/2 study of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. Ended

2023-504363-17-00 Advanced MTAP-null solid tumors 2022-05-13
Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended

2024-510655-36-00 Advanced Malignancies Associated with EphA2 Expression 2022-02-01
Safety and Efficacy of AMT-130 in European Adults with Early Manifest Huntington Disease Ended

2024-511766-37-00 Huntington’s Disease 2021-10-07
A trial to learn how safe rilvegostomig (AZD2936) is, how it moves throughout the body over time, and how well it works in adults with advan… Ended

2023-508262-15-00 Advanced Non-small Cell Lung Cancer, Metastatic Non-sma 2021-09-09
Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended

2022-502856-29-00 Advanced Solid Tumors 2021-07-27
Actuate 1801: Elraglusib (9-ING-41) is an investigational study drug give alone or in combination with other chemotherapies, for the potenti… Ended

2024-518409-16-00 Refractory Hematologic Malignancies or Solid Tumors 2021-04-14
Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies. Ended

2023-509781-37-00 Nectin-4 Expressing Advanced Malignancies. 2021-04-12
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexande… Ended

2024-510603-11-00 Alexander Disease 2021-04-08
CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL Ended

2024-519174-39-00 Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia 2021-02-15
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 2020-10-30
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced C… Ended

2024-517536-22-00 Unresectable or metastatic cutaneous squamous cell carc 2020-09-22
Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended

2023-507062-34-00 High-Risk large B-Cell lymphoma 2020-08-07
A first-in-human clinical study to assess feasibility, safety and antitumor activity of genetically modified T-cells in multiple myeloma Ended

2024-512643-23-00 Multiple myeloma 2020-06-22
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients wit… Ended

2024-514933-39-00 Patients with Advanced Tumors and Tenosynovial Giant Ce 2020-05-26
First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended

2024-515560-30-00 Advanced-stage, relapsed/refractory cancer 2020-03-05
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended

2023-509550-55-00 Multiple Myeloma 2020-01-21
GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended

2023-508526-10-00 Malignant solid tumors: Patients with relapsed or refra 2019-10-01